IDS I20
LIVE

Serial Number

79225752

Owner

Immunodiagnostic Systems Limited

Attorney

Kevan L. Morgan

Filing Date

Oct 23, 2017

Add to watchlist:

No watchlists yet
View on USPTO

IDS I20 Trademark

Serial Number: 79225752 • Registration: 5635057

IDS I20 is a trademark filed by Immunodiagnostic Systems Limited on October 23, 2017. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Immunodiagnostic Systems Limited (6 trademarks)

10 Didcot Way, Boldon Business Park

Entity Type: 99

Trademark Details

Filing Date

October 23, 2017

Registration Date

December 25, 2018

Published for Opposition

October 9, 2018

Cancellation Date

July 11, 2025

Goods & Services

Reagents for use in diagnostic tests, namely, diagnostic kits comprised primarily of medical diagnostic reagents for testing of bodily fluids for use in disease detection, namely, diseases and disorders in the areas of endocrinology, clinical chemistry, autoimmunity, infectious diseases, allergy, hemostasis, coagulation, hematology, immunology, therapeutic drug monitoring, oncology markers, other biomarkers, and immunochemistry for medical purposes; chemical diagnostic reagents for medical use; diagnostic preparations, namely, diagnostic reagents for medical use; diagnostic testing materials, namely, immunoassays and chemistry tests for measuring analytes for use in diseases and disorders in the areas of endocrinology, clinical chemistry, autoimmunity, infectious diseases, allergy, hemostasis, coagulation, hematology, immunology, therapeutic drug monitoring, oncology markers, other biomarkers, and immunochemistry for medical use; reagents for use in diagnostic tests; chemical preparations for testing blood for use in disease detection, namely, diseases and disorders in the areas of endocrinology, clinical chemistry, autoimmunity, infectious diseases, allergy, hemostasis, coagulation, hematology, immunology, therapeutic drug monitoring, oncology markers, other biomarkers, and immunochemistry for medical purposes; diagnostic reagents for medical use for sale in kit form, namely diagnostic kits comprised primarily of medical diagnostic reagents for testing of bodily fluids for use in disease detection, namely, diseases and disorders in the areas of endocrinology, clinical chemistry, autoimmunity, infectious diseases, allergy, hemostasis, coagulation, hematology, immunology, therapeutic drug monitoring, oncology markers, other biomarkers, and immunochemistry

Diagnostic reagents for scientific or research use; diagnostic reagents for in vitro use other than medical, namely, research or scientific investigation in the areas of immunochemistry, immunology, clinical chemistry, biochemistry, microbiology, hematology, and hemostasis; diagnostic test reagents, chemical and biochemical reagents, and preparations for determining the presence or concentration of an analyte for clinical, scientific or research purposes; diagnostic preparations for scientific or research use; assays and reagents for research purposes; biological and biochemical reagents, used for non-medical purposes, namely, for research and commercial use in the nature of biochemical or biological analysis

Instruments, namely, scientific instruments, namely, automated analyzers for testing and analyzing chemical and biological substances for the presence, absence or quantity of biological analytes or target chemicals, or instruments using automated detection methods for detecting and identifying chemical and biological substances, not for medical purposes, for testing, processing or detecting biological samples; computer software for use in analyzing and managing biological data

Medical diagnostic apparatus for medical purposes, namely, diagnostic instruments for medical use in immunoassay and clinical chemistry testing such as electromagnetic medical diagnostic imaging apparatus; medical diagnostic testing instruments for use in immunoassay medical procedures, namely, medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; medical diagnostic instruments, namely, medical instrument for cardiovascular diagnostics; blood testing apparatus

Filing History

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Mar 11, 2026 INTR
CANCELLED SECTION 71
Jul 11, 2025 C71T
NEW REPRESENTATIVE AT IB RECEIVED
May 8, 2025 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Dec 25, 2023 REM3
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 6, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 6, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 6, 2023 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 6, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 6, 2023 COAR
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 26, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 9, 2019 FICS
FINAL DISPOSITION PROCESSED
Apr 9, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 25, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Dec 25, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 9, 2018 NPUB
PUBLISHED FOR OPPOSITION
Oct 9, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Oct 6, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 19, 2018 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Sep 19, 2018 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 19, 2018 NONP
ASSIGNED TO LIE
Sep 4, 2018 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 20, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 31, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 30, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 30, 2018 TROA
REFUSAL PROCESSED BY IB
Mar 2, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 14, 2018 RFCS
REFUSAL PROCESSED BY MPU
Feb 14, 2018 RFRR
APPLICATION FILING RECEIPT MAILED
Feb 9, 2018 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 8, 2018 RFCR
NON-FINAL ACTION WRITTEN
Feb 7, 2018 CNRT
ASSIGNED TO EXAMINER
Feb 5, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 5, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 1, 2018 REPR